Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Arch Razi Inst ; 77(2): 717-725, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-36284953

RESUMEN

Burkholderia cepacia is found as part of the B. cepacia complex (Bcc), a collection of highly pathogenic organisms. The Bcc is present almost everywhere in nature; however, it is most prevalent in damp settings, plant roots, and soils. Moreover, Bcc is a major source of morbidity and death in patients due to its high intrinsic antibiotic resistance. The present study aims to isolate and identify gram-negative aerobic bacteria from clinical samples derived from a variety of pathological diseases and investigate the bacterium's virulence factors and genes. The current study included 250 specimens collected from patients suffering from diabetic foot ulcers, urine, burn, wound, sputum, and discharge from the eyes. The samples were collected from both sexes with the age range of 1-75 years. The recorded data showed that males had a higher frequency of infection (79.2%) than females (52%). The results revealed that 7.6% of infected females were between 1-15 years old, while 22% of infected males were aged between 31-45 years. In addition, 26.8% of infected patients (both males and females) were aged between 31-45 years.


Asunto(s)
Infecciones por Burkholderia , Complejo Burkholderia cepacia , Burkholderia cepacia , Fibrosis Quística , Femenino , Masculino , Burkholderia cepacia/genética , Complejo Burkholderia cepacia/genética , Infecciones por Burkholderia/diagnóstico , Infecciones por Burkholderia/epidemiología , Infecciones por Burkholderia/microbiología , Fibrosis Quística/microbiología , Probabilidad , Suelo , Factores de Virulencia , Humanos , Adulto , Persona de Mediana Edad
2.
Auton Autacoid Pharmacol ; 22(5-6): 241-6, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12866803

RESUMEN

1 This study examined the potentiating effects of competitive antagonists of the adrenergic alpha2 receptors and of phenoxybenzamine (POB) an irreversible antagonist, on the stimulation-induced efflux of [3H]-noradrenaline in arterial tissue of rabbit. This was done to determine if the lack of concordance of efflux potentiation by antagonists with the expectations of presynaptic negative feedback theory can be attributed to increasingly successful competition from rising perineuronal transmitter concentrations, when stimulation parameters are increased, in the presence of a fixed concentration of competitive antagonist. 2 Tissues were stimulated with a fixed pulse number and frequency, to rule out confounding factors, and major alterations in the concentration of released transmitter were achieved through variations in the pulse duration. 3 Rauwolscine potentiated transmitter release less at the longest, rather than at the shortest pulse duration, and showed a potentiation of release that was indifferent to the quantities of released transmitter. This was also seen with POB although it binds covalently to the presynaptic receptor. 4 Noradrenaline inhibited stimulation-induced transmitter release confirming the presence of presynaptic alpha inhibitory sites. 5 Yohimbine potentiated transmitter release the same as did rauwolscine and POB, and protected the relevant sites against POB potentiation, confirming site identity. The combination of POB and rauwolscine had no greater effect than did either alone certifying that they acted similarly and that maximally effective concentrations of each were used. 6 Consequently, noradrenaline breakthrough of presynaptic receptor blockade does not explain the non-conforming observations made with competitive antagonists in tests of presynaptic theory.


Asunto(s)
Antagonistas Adrenérgicos alfa/farmacología , Arterias/metabolismo , Neurotransmisores/metabolismo , Agonistas de Receptores Adrenérgicos alfa 2 , Animales , Aorta/efectos de los fármacos , Aorta/metabolismo , Arterias/efectos de los fármacos , Unión Competitiva/efectos de los fármacos , Estimulación Eléctrica , Técnicas In Vitro , Norepinefrina/metabolismo , Fenoxibenzamina/farmacología , Conejos , Receptores Presinapticos/efectos de los fármacos , Yohimbina/farmacología
3.
Brain Res Bull ; 55(6): 761-5, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11595360

RESUMEN

Endogenous adrenergic drive regulates the firing rate of serotonergic neurons. However, advocates of feedback theory assert that 5-hydroxytryptamine (5-HT) released in the somatodendritic region of raphe neurons regulates both rate and release of 5-HT. Experiments were done to determine if the somatodendritic region might have receptors for norepinephrine that inhibit release of 5-HT independently of rate, as this would allow for discrete effects of norepinephrine on rate and release, even in the presence of functional feedback by 5-HT. The release of 5-HT at fixed frequencies of stimulation was substantially reduced when norepinephrine (1 and 3 x 10(-7) M) was present. Norepinephrine also inhibited the release of 3H-5-HT with delivery of a single stimulation pulse ruling out a remote action of the catecholamine. The alpha(1) antagonist prazosin did not modify the profile of norepinephrine inhibition. Further, the alpha(1) agonist phenylephrine had no effect on 3H-5-HT efflux. The alpha(2) antagonist yohimbine antagonized almost entirely the inhibition by norepinephrine at 1 Hz, and reduced it substantially at 3 Hz. Blockade of 5-HT(1) receptor sites with methiothepin did not reduce the inhibitory effect of norepinephrine on 3H-5-HT efflux. It is proposed that release of endogenous norepinephrine at synapses with 5-HT neurons could activate 5-HT neuron firing rate through alpha(1) receptors located at the soma and simultaneously short-circuit ongoing 5-HT feedback inhibition by inhibiting release through adrenergic alpha two receptors likely located at the dendrites.


Asunto(s)
Retroalimentación/fisiología , Fluoxetina/análogos & derivados , Inhibición Neural/fisiología , Neuronas/metabolismo , Norepinefrina/metabolismo , Núcleos del Rafe/metabolismo , Receptores Adrenérgicos/metabolismo , Serotonina/metabolismo , Agonistas alfa-Adrenérgicos/farmacología , Antagonistas Adrenérgicos alfa/farmacología , Animales , Dendritas/efectos de los fármacos , Dendritas/metabolismo , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Retroalimentación/efectos de los fármacos , Fluoxetina/farmacología , Mesencéfalo/efectos de los fármacos , Mesencéfalo/metabolismo , Metiotepina/farmacología , Inhibición Neural/efectos de los fármacos , Neuronas/efectos de los fármacos , Norepinefrina/farmacología , Fenilefrina/farmacología , Prazosina/farmacología , Conejos , Núcleos del Rafe/efectos de los fármacos , Receptores Adrenérgicos/efectos de los fármacos , Antagonistas de la Serotonina/farmacología , Yohimbina/farmacología
4.
J Auton Pharmacol ; 21(3): 145-9, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11844022

RESUMEN

1. The linkage between potentiation of field stimulation-induced noradrenaline release and blockade of the presynaptic inhibitory effect of exogenous noradrenaline by a presynaptic antagonist was examined in superfused rabbit aorta preparations. 2. Rauwolscine clearly potentiated the release of noradrenaline in response to 100 pulses at 2 Hz but reduced the capacity of noradrenaline to inhibit transmitter release to a questionable extent, and then only when comparisons were made with untreated, rather then to rauwolscine-treated, controls. 3. Aortic preparations exposed for 60 min to rauwolscine followed by superfusion with antagonist-free Krebs for 60 min retained the potentiation of stimulation-induced transmitter release but no antagonism of the noradrenaline-induced inhibition could be detected at either of two noradrenaline concentrations when comparisons were made with rauwolscine treated controls. 4. Comparisons of the inhibitory effect of exogenous noradrenaline (1.8 x 10-6 M) on transmitter efflux in the presence and absence of rauwolscine pretreatment revealed that the antagonist enhanced rather than antagonized the presynaptic inhibition by noradrenaline. 5 It is concluded that the unitary hypothesis that asserts that antagonist enhancement of transmitter release and its blockade of noradrenaline induced inhibition are manifestations of a unitary event are not supportable.


Asunto(s)
Agonistas Adrenérgicos/farmacología , Antagonistas Adrenérgicos/farmacología , Agonistas de Receptores Adrenérgicos alfa 2 , Receptores Presinapticos/agonistas , Receptores Presinapticos/antagonistas & inhibidores , Antagonistas de Receptores Adrenérgicos alfa 2 , Animales , Aorta/efectos de los fármacos , Aorta/metabolismo , Norepinefrina/biosíntesis , Norepinefrina/metabolismo , Conejos , Receptores Adrenérgicos alfa 2/metabolismo , Receptores Presinapticos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA